Ahmedabad-based pharma major Cadila Healthcare (Zydus Cadila) has announced an accelerated research programme for developing a vaccine for the novel coronavirus, (COVID-19) with multiple teams in India and Europe.
Given the extent and rapidity of the global spread of the virus, which originated in China, the fast-tracked research programme will be based on two approaches, including development of a DNA vaccine and a live attenuated recombinant measles virus vaccine. The epidemic, which was detected last December, has claimed around 1,500 lives and infected over 66,000 people.
“There is an urgent and pressing need to develop a safe and efficacious vaccine that can